Marta Meyers, MD
Internal Medicine · Morristown, NJNPI 1154328755
Payments from drug & device makers
Across 311 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$648
- Pfizer$447
- Lilly USA, LLC$435
- Amgen$390
- Novo Nordisk$375
- GSK$300
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,776100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $648 |
| Pfizer | 31 | $447 |
| Lilly USA, LLC | 28 | $435 |
| Amgen | 27 | $390 |
| Novo Nordisk | 24 | $375 |
| GSK | 18 | $300 |
| AstraZeneca | 16 | $231 |
| Exact Sciences | 8 | $198 |
| Johnson & Johnson | 13 | $192 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $149 |
| Merck | 10 | $137 |
| Boehringer Ingelheim | 8 | $117 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $99 |
| Almatica Pharma LLC | 6 | $88 |
| Kowa Pharmaceuticals America, Inc. | 6 | $88 |
| Avanir Pharmaceuticals, Inc. | 4 | $82 |
| Novartis | 4 | $69 |
| Amarin Pharma, Inc. | 5 | $68 |
| Azurity Pharmaceuticals, Inc. | 4 | $68 |
| Sanofi Pasteur Inc. | 4 | $65 |
| Bausch Health US, LLC | 4 | $61 |
| Idorsia Pharmaceuticals US Inc | 4 | $59 |
| Abbott | 3 | $49 |
| Nevro Corp. | 2 | $42 |
| Astellas Pharma US Inc | 2 | $36 |
| Dexcom, Inc. | 1 | $35 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| IBSA Pharma Inc. | 1 | $20 |
| Bayer | 1 | $18 |
| Amphastar Pharmaceuticals, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Dynavax Technologies Corporation | 1 | $13 |
| Agios Pharmaceuticals, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$4,776 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 45 | $52,026 |
| XareltoRivaroxaban | 27 | $44,533 |
| JardianceEmpagliflozin | 22 | $37,408 |
| MounjaroTirzepatide | 20 | $22,189 |
| JanuviaSitagliptin Phosphate | 14 | $18,718 |
| MyrbetriqMirabegron | 11 | $10,113 |
| OzempicSemaglutide | 11 | $9,143 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $8,921 |
| Valsartan | 199 | $6,384 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 102 | $5,336 |
| Atorvastatin Calcium | 465 | $4,942 |
| Celecoxib | 25 | $2,662 |
| Levothyroxine Sodium | 237 | $2,547 |
| Escitalopram Oxalate | 125 | $2,311 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 57 | $2,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $447 | $52,02645 claims |
| Johnson & JohnsonXarelto | $192 | $44,53327 claims |
| Boehringer IngelheimJardiance | $117 | $37,40822 claims |
| Lilly USA, LLCMounjaro | $435 | $22,18920 claims |
| MerckJanuvia | $137 | $18,71814 claims |
| Astellas Pharma US IncMyrbetriq | $36 | $10,11311 claims |
| Novo NordiskOzempic | $375 | $9,14311 claims |
| GSKBreo Ellipta | $300 | $8,92123 claims |
| AbbVieSynthroid | $648 | $1,64722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Morristown
- David ShulkinMorristown$1.7M
- Jan Schwarz-MillerMorristown$87K
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.